Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 Active Not Recruiting Phase 2 Trials for Irinotecan (DB00762)

IndicationStatusPhase
DBCOND0113388 (Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03641313Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction CancerTreatment